Equities
European metals stocks poised for gains if U.S.-Canada tariffs halve
Morgan Stanley analysis projects ArcelorMittal as the top beneficiary, with potential annualized pre-tax relief of $300-$350 million. Rio Tinto, SSAB and Norsk Hydro face mixed impacts.
Harrow’s eye anesthesia gel shows 58% less discomfort in study
IHEEZO gel outperformed proparacaine in a 50-patient trial, with statistically significant reductions in pain across all post-injection time points.
IntraGel raises $7M from UroGen for head and neck cancer therapy
Funds will advance TumoCure through Phase 2 trials after Phase 1b data showed safety and early efficacy. UroGen gains exclusive global rights option under the deal.
Aryzta shares drop 6% after UBS downgrades to sell on margin concerns
Swiss bakery group’s stock falls as UBS cuts price target to CHF40 and slashes earnings forecasts, citing weaker growth and margin pressures in Germany and GLP-1 diet trends.
US equities mixed; SMI edges lower as oil hits four-week high
Futures on the Dow slipped 0.13% while Nasdaq futures rose 0.1% ahead of U.S. open. Brent crude surged 2.6% to $94.04/bbl, nearing $100/bbl. Swiss Re and Logitech led SMI laggards.
LSI Industries CFO to retire in August 2027 after decade-long tenure
James E. Galeese, CFO since 2017, will step down after over 10 years with the Cincinnati-based lighting and display manufacturer. The company plans to name a successor by mid-2027.
D.E. Shaw discloses $1B+ stake in Sysco amid AI push
Hedge fund D.E. Shaw reveals a more than $1 billion stake in Sysco, as the food distributor accelerates AI-driven efficiency gains and eyes a major acquisition. Sysco’s stock has underperformed over the past year.
Michelin shares rise 1.7% after JPMorgan upgrade to Overweight
Stock climbs to €34.68 as JPMorgan lifts price target to €42, citing accelerating truck tire demand and durable growth in high-tech composites.
Ultragenyx surges 11% after FDA approval of gene therapy for rare disease
Ultragenyx shares jumped 11.1% in pre-market trading after the FDA granted accelerated approval for GENGLYCOS, the company's first gene therapy. Analysts raised price targets to as high as $58.
Target’s grocery push drives traffic growth, but broader shopper appeal remains key
Food and beverage sales rose 7% in the latest quarter as Target expands private-label offerings, yet grocery still accounts for less than a quarter of total merchandise sales.
Robo.ai to release H1 2026 results Sunday after restructuring
The Abu Dhabi-based AI firm will file unaudited financials with the SEC on Sunday, following the disposal of legacy operations and acquisition of Neurovia AI and Quantum Core Capital.
Hays profit rises 3% in FY26 as £50m cost cuts offset fee decline
Pre-exceptional operating profit increased to £48.6m despite an 8% drop in net fees to £905.5m, as restructuring delivered £50m in annualized savings ahead of schedule.
Swiss Prime Site posts 5.1% EPS growth, portfolio value tops CHF 14bn
H1 2026 results show funds from operations per share at CHF 2.15, with full-year guidance raised to the upper end of CHF 4.25-4.30. Asset management AuM rose to CHF 14.8bn.
Swiss Market Index slips 0.26% as Logitech, Swiss Re lead declines
Logitech and Swiss Re shares drop nearly 3% each as SMI falls 0.26%, while Aryzta hits multi-year low after UBS downgrade. Oil near $94, Brent nears $100 as inflation concerns resurface.
Euro Stoxx 50 falls as yields, oil rise; Swiss SMI supported by China trade deal
Eurozone blue-chip index down 0.35% as bond yields climb and crude oil advances; Swiss SMI pares losses to 0.13% on China trade pact. JD Sports drops 14% on weak outlook; Eni, BP gain on higher oil.
Basilea shares hit eight-year high after strong H1 results
Swiss biopharma firm’s stock surges 3% to CHF 64.30 as first-half revenue beats expectations, driven by Cresemba’s global uptake. Patent cliff looms from late 2027.
Latitude Financial posts 39% H1 2026 profit rise, declares AUD 0.055 dividend
Half-year cash profit surged 39% to AUD 64.3 million as receivables topped AUD 7.3 billion. Interim dividend set at AUD 0.055 per share, fully franked.
Morgan Stanley lifts semiconductor equipment outlook on stronger DRAM demand
Analysts raise 2026 and 2027 wafer fabrication equipment forecasts as DRAM investment accelerates. Advantest remains top pick after raising guidance.
Ascelia Pharma shares surge 8.2% after FDA setback on Orviglance
Swedish biotech advances despite Complete Response Letter on lead MRI contrast agent; cash runway extended into Q2 2027 after cost cuts.
Nanoform cuts Q2 2026 cash burn to EUR 1.5m as regulatory progress accelerates
Finnish drugmaker trims first-half spending by 33% year-on-year while securing $1m deal and advancing nanoenzalutamide toward market authorization.
Clavister posts 63% sales growth, record 30% EBITDA margin in Q2 2026
Swedish cybersecurity firm Clavister reported a 63% year-over-year surge in net sales to 89.2 million Swedish kronor, alongside a record 30% adjusted EBITDA margin. Defence segment revenue surged 370% to 47 million kronor.
Gubra reports H1 2026 profit rebound, obesity pipeline progress
Danish biotech firm returns to profit in H1 2026 as CRO arm grows, while obesity pipeline advances with Phase 2 milestones and new drug candidates.
Swiss ETF savings plans surge 44.6% in H1 2026, led by global index funds
Broadly diversified world ETFs dominate Swiss savings plans despite AI and ESG hype, with monthly volume up 29% in Europe. Swiss adoption remains low at 9% of investors.
Accent Group posts A$13.8m loss, unveils FY2026 strategic reset
Australian footwear retailer Accent Group reported a statutory net loss of A$13.8m for FY2026 while outlining a multi-year portfolio overhaul targeting A$40m in cost savings and A$14m EBIT lift by 2030.